Loading provider…
Loading provider…
Hematology & Oncology Physician in New Hyde Park, NY
NPI: 1407927593Primary Practice Location
NORTHWELL HOSPITAL GLEN COVE
101 Saint Andrews Ln, Glen Cove, NY
Primary Employer
Northwell Health Center for Advance Medicine
cancer.northwell.edu
HQ Phone
Get MD Craig's Phone Numberphone_androidMobile
Get MD Craig's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
NYU Long Island School of Medicine
Residency • Internal Medicine
1994 - 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 170 | 551 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 88 | 144 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 76 | 94 |
| 4 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 46 | 53 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 45 | 45 |
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
Authors: David Tuveson, Christopher Wolfgang, Michelle Ma, Allyson Ocean, Peter Allen, James Crawford, Cinthya Lowder, Richard Burkhart, Joseph Kim, Andrew Aguirre, Jasmine Huynh, Kenneth Yu, Divyesh Sejpal, Jonathan Buscaglia, Austin Goetz, Jordan Winter, Edward Kim, Aaron Sasson, Juan Carlos Bucobo, Jean Grem
Publication Date: 2018-05-31
BRAF inhibitors - do we need to worry about kidney injury?
Lead Sponsor: Elicio Therapeutics
Intervention / Treatment: DRUG: ELI-002 2P
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Quality-of-Life Assessment, DRUG: Fluorouracil, DRUG: Bevacizumab, DRUG: Oxaliplatin, DRUG: Irinotecan, DIETARY_SUPPLEMENT: Cholecalciferol, DRUG: Irinotecan Hydrochloride, DRUG: Leucovorin Calcium
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, BIOLOGICAL: Pembrolizumab, PROCEDURE: Biospecimen Collection, PROCEDURE: Therapeutic Conventional Surgery, PROCEDURE: Computed Tomography